Semaglutide’s MASH Benefits Extend Beyond Weight Loss

By News Health
2 hours Ago

(MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according…

Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118430

Author :

Publish date : 2025-11-10 22:07:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

What Your Patients Should Know About GLP-1s and Melatonin

Common Everyday Meds Linked to Worse Outcomes in Breast Cancer Patients

Saroglitazar for MASLD Cuts Liver Fat in Women With Polycystic Ovary Syndrome

FDA Plans to Pull Black Box Warnings From HRT Products

FDA Advisors Explore a Possible Future With Chatbot Mental Health Care

How Does Gender Affect Heart Health?